BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Subscribe To Our Newsletter & Stay Updated
